TY - JOUR
T1 - Discovery and validation of autosomal dominant Alzheimer's disease mutations
AU - Hsu, Simon
AU - Gordon, Brian A.
AU - Hornbeck, Russ
AU - Norton, Joanne B.
AU - Levitch, Denise
AU - Louden, Adia
AU - Ziegemeier, Ellen
AU - Laforce, Robert
AU - Chhatwal, Jasmeer
AU - Day, Gregory S.
AU - McDade, Eric
AU - Morris, John C.
AU - Fagan, Anne M.
AU - Benzinger, Tammie L.S.
AU - Goate, Alison M.
AU - Cruchaga, Carlos
AU - Bateman, Randall J.
AU - Karch, Celeste M.
N1 - Publisher Copyright:
© 2018 The Author(s).
PY - 2018/7/18
Y1 - 2018/7/18
N2 - Background: Alzheimer's disease (AD) is a neurodegenerative disease that is clinically characterized by progressive cognitive decline. Mutations in amyloid-β precursor protein (APP), presenilin 1 (PSEN1), and presenilin 2 (PSEN2) are the pathogenic cause of autosomal dominant AD (ADAD). However, polymorphisms also exist within these genes. Methods: In order to distinguish polymorphisms from pathogenic mutations, the DIAN Expanded Registry has implemented an algorithm for determining ADAD pathogenicity using available information from multiple domains, including genetic, bioinformatic, clinical, imaging, and biofluid measures and in vitro analyses. Results: We propose that PSEN1 M84V, PSEN1 A396T, PSEN2 R284G, and APP T719N are likely pathogenic mutations, whereas PSEN1 c.379-382delXXXXinsG and PSEN2 L238F have uncertain pathogenicity. Conclusions: In defining a subset of these variants as pathogenic, individuals from these families can now be enrolled in observational and clinical trials. This study outlines a critical approach for translating genetic data into meaningful clinical outcomes.
AB - Background: Alzheimer's disease (AD) is a neurodegenerative disease that is clinically characterized by progressive cognitive decline. Mutations in amyloid-β precursor protein (APP), presenilin 1 (PSEN1), and presenilin 2 (PSEN2) are the pathogenic cause of autosomal dominant AD (ADAD). However, polymorphisms also exist within these genes. Methods: In order to distinguish polymorphisms from pathogenic mutations, the DIAN Expanded Registry has implemented an algorithm for determining ADAD pathogenicity using available information from multiple domains, including genetic, bioinformatic, clinical, imaging, and biofluid measures and in vitro analyses. Results: We propose that PSEN1 M84V, PSEN1 A396T, PSEN2 R284G, and APP T719N are likely pathogenic mutations, whereas PSEN1 c.379-382delXXXXinsG and PSEN2 L238F have uncertain pathogenicity. Conclusions: In defining a subset of these variants as pathogenic, individuals from these families can now be enrolled in observational and clinical trials. This study outlines a critical approach for translating genetic data into meaningful clinical outcomes.
KW - APP
KW - Autosomal dominant Alzheimer's disease
KW - Cell-based assays
KW - PSEN1
KW - PSEN2
KW - Pathogenicity algorithm
UR - http://www.scopus.com/inward/record.url?scp=85050349047&partnerID=8YFLogxK
U2 - 10.1186/s13195-018-0392-9
DO - 10.1186/s13195-018-0392-9
M3 - Article
C2 - 30021643
AN - SCOPUS:85050349047
SN - 1758-9193
VL - 10
JO - Alzheimer's Research and Therapy
JF - Alzheimer's Research and Therapy
IS - 1
M1 - 67
ER -